(Q35609549)

9 August 2017

1 reference

title

Brachytherapy for prostate cancer: follow-up and management of treatment failures (English)

1 reference

9 August 2017

1 reference

Eric M Horwitz

1

1 reference

9 August 2017

Robert G Uzzo

series ordinal

2

1 reference

9 August 2017

Nicole Miller

series ordinal

3

1 reference

9 August 2017

Dan Theodorescu

series ordinal

4

1 reference

9 August 2017

language of work or name

1 reference

1 November 2003

1 reference

Urologic Clinics of North America

9 August 2017

1 reference

9 August 2017

30

1 reference

9 August 2017

4

1 reference

9 August 2017

737-50, viii-ix

1 reference

Acute urinary morbidity following I-125 interstitial implantation of the prostate gland

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Temporal resolution of urinary morbidity following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

An improved method for computerized tomography-planned transperineal 125iodine prostate implants

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Palladium-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Isotope selection for patients undergoing prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Rectal function following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Lack of prostate cancer radiosensitization by androgen deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

The role of androgen deprivation therapy combined with prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Permanent radioactive seed implantation in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Geometric reconstruction of seed implants using a three-film technique.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

A CT-based evaluation method for permanent implants: application to prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

CT-based dosimetry for transperineal I-125 prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Impact of ultrasound and computed tomography prostate volume registration on evaluation of permanent prostate implants

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

The impact of edema on planning 125I and 103Pd prostate implants

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

A dose-response study for I-125 prostate implants

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Treatment options for localized recurrence of prostate cancer following radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

No difference in biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Salvage radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Salvage radical prostatectomy after radiation therapy and brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Salvage radical prostatectomy in the management of locally recurrent prostate cancer after 125I implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Salvage brachytherapy for localized prostate cancer after radiotherapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

The efficacy and complications of salvage cryotherapy of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900059-4

7 January 2021

10.1016/S0094-0143(03)00059-4

Identifiers

DOI

1 reference

9 August 2017

1 reference